Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Apr;16(4):132-143.
doi: 10.5489/cuaj.7621.

Considerations on the identification and management of metastatic prostate cancer patients with DNA repair gene alterations in the Canadian context

Michael P Kolinsky  1 , Karen Y Niederhoffer  2 , Edmond M Kwan  3 , Sebastien J Hotte  4 , Zineb Hamilou  5 , Steven M Yip  6 , Kim N Chi  7 , Alexander W Wyatt  8 , Fred Saad  9
Affiliations
Review

Considerations on the identification and management of metastatic prostate cancer patients with DNA repair gene alterations in the Canadian context

Michael P Kolinsky et al. Can Urol Assoc J. 2022 Apr.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests: Dr Kolinsky has received honoraria and/or consulting fees from and has participated in industry-sponsored clinical trials for Astellas, AstraZeneca, Bayer, BMS, Eisai, Ipsen, Janssen, and Merck. Dr. Kwan is an advisory board member for Astellas, Ipsen, and Janssen; has received compensation in the form of travel/accommodations from Astellas, Ipsen, Pfizer, and Roche; and has received grants and/or honoraria from Astellas Pharma, Ipsen, and Janssen. Dr. Hotte has been an advisory board member for AAA/Novartis, Astellas, Bayer, BMS, Eisai, Ipsen, Janssen, Merck, Pfizer, and Seagen; has received grants/honoraria from Astellas, Bayer, BMS, and Janssen; and has participated in clinical trials supported by AAA/Novartis, Astellas, BMS, CCTG, Eisai, Merck, Pfizer, SeaGen, and SignalChem. Dr. Hamilou has received payment for presentations from AstraZeneca, EMD Serono, and Sengen; and has participated in a clinical trial supported by Sengen. Dr. Yip has been an advisory board member for and received honoraria from AstraZeneca, Bayer, BMS, Hoffman-La Roche, Ipsen, Janssen, Merck, Novartis, and Pfizer; and has participated in clinical trials supported by AstraZeneca and Pfizer. Dr. Chi has received payments for consulting services from Astellas, AstraZeneca, Daiichi Sankyo, Janssen, Novartis, Pfizer, Point Biopharma, Roche, and Sanofi; and has received educational speaker honoraria and research grants from Astellas, AstraZeneca, Janssen, Novartis, Point Biopharma, Roche, and Sanofi. Dr. Wyatt has received honoraria from Astellas, AstraZeneca, Janssen, and Merck; and has received a research grant from Janssen. Dr. Saad has received grant(s) and/or honoraria from Astellas, Astra Zeneca, Bayer, Janssen, Knight, Myovant, Novartis, Pfizer, and Sanofi. The remaining authors do not report any competing personal or financial interests related to this work.

Figures

Fig. 1
Fig. 1
A schematic representation of mainstreaming germline genetic testing compared to the traditional pathway of referral to a Hereditary Cancer Clinic (HCC). VUS: variant of uncertain significance.
See this image and copyright information in PMC

References

    1. Huggins C, Hodges C. Studies on prostatic cancer. I. The effect of castration, of estrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1:293–7.
    1. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–12. doi: 10.1056/NEJMoa040720. - DOI - PubMed
    1. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomized, open-label trial. Lancet. 2010;376:1147–54. doi: 10.1016/S0140-6736(10)61389-X. - DOI - PubMed
    1. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995–2005. doi: 10.1056/nejmoa1014618. - DOI - PMC - PubMed
    1. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187–97. doi: 10.1056/NEJMoa1207506. - DOI - PubMed

LinkOut - more resources